Putative mechanisms of action of statins in multiple sclerosis - Comparison to interferon-β and glatiramer acetate

Oliver Neuhaus, Olaf Stüve, Juan J. Archelos, Hans Peter Hartung

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase and are widely prescribed as cholesterol-lowering agents. They are promising candidates for future treatment in multiple sclerosis (MS) as they have been shown to exhibit immunomodulatory effects. Recent reports have demonstrated that statins are effective in preventing and reversing chronic and relapsing experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Furthermore, in vitro experiments with human immune cells have documented an immunomodulatory mode of action of statins comparable to that of interferon (IFN)-β. An open label clinical trial assessing simvastatin in MS revealed a significant decrease in the number and volume of new MRI lesions and a favourable safety profile. This article reviews data thus far present on the putative mechanisms of action of statins in the immunopathogenesis of MS. Furthermore, the role of statins as potential pharmacotherapy for MS is discussed in the context of the mechanisms of approved immunotherapies in MS, namely IFN-β and glatiramer acetate (GA).

Original languageEnglish (US)
Pages (from-to)173-177
Number of pages5
JournalJournal of the Neurological Sciences
Volume233
Issue number1-2
DOIs
StatePublished - Jun 15 2005

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Interferons
Multiple Sclerosis
Simvastatin
Autoimmune Experimental Encephalomyelitis
Immunotherapy
Glatiramer Acetate
Oxidoreductases
Animal Models
Cholesterol
Clinical Trials
Safety
Drug Therapy

Keywords

  • Glatiramer acetate
  • Immunomodulation
  • Immunotherapy
  • Interferon-β
  • Multiple sclerosis
  • Statins

ASJC Scopus subject areas

  • Aging
  • Clinical Neurology
  • Surgery
  • Developmental Neuroscience
  • Neurology
  • Neuroscience(all)

Cite this

Putative mechanisms of action of statins in multiple sclerosis - Comparison to interferon-β and glatiramer acetate. / Neuhaus, Oliver; Stüve, Olaf; Archelos, Juan J.; Hartung, Hans Peter.

In: Journal of the Neurological Sciences, Vol. 233, No. 1-2, 15.06.2005, p. 173-177.

Research output: Contribution to journalArticle

@article{a901b4a8b21943b2ae057b2e1b173080,
title = "Putative mechanisms of action of statins in multiple sclerosis - Comparison to interferon-β and glatiramer acetate",
abstract = "Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase and are widely prescribed as cholesterol-lowering agents. They are promising candidates for future treatment in multiple sclerosis (MS) as they have been shown to exhibit immunomodulatory effects. Recent reports have demonstrated that statins are effective in preventing and reversing chronic and relapsing experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Furthermore, in vitro experiments with human immune cells have documented an immunomodulatory mode of action of statins comparable to that of interferon (IFN)-β. An open label clinical trial assessing simvastatin in MS revealed a significant decrease in the number and volume of new MRI lesions and a favourable safety profile. This article reviews data thus far present on the putative mechanisms of action of statins in the immunopathogenesis of MS. Furthermore, the role of statins as potential pharmacotherapy for MS is discussed in the context of the mechanisms of approved immunotherapies in MS, namely IFN-β and glatiramer acetate (GA).",
keywords = "Glatiramer acetate, Immunomodulation, Immunotherapy, Interferon-β, Multiple sclerosis, Statins",
author = "Oliver Neuhaus and Olaf St{\"u}ve and Archelos, {Juan J.} and Hartung, {Hans Peter}",
year = "2005",
month = "6",
day = "15",
doi = "10.1016/j.jns.2005.03.030",
language = "English (US)",
volume = "233",
pages = "173--177",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Putative mechanisms of action of statins in multiple sclerosis - Comparison to interferon-β and glatiramer acetate

AU - Neuhaus, Oliver

AU - Stüve, Olaf

AU - Archelos, Juan J.

AU - Hartung, Hans Peter

PY - 2005/6/15

Y1 - 2005/6/15

N2 - Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase and are widely prescribed as cholesterol-lowering agents. They are promising candidates for future treatment in multiple sclerosis (MS) as they have been shown to exhibit immunomodulatory effects. Recent reports have demonstrated that statins are effective in preventing and reversing chronic and relapsing experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Furthermore, in vitro experiments with human immune cells have documented an immunomodulatory mode of action of statins comparable to that of interferon (IFN)-β. An open label clinical trial assessing simvastatin in MS revealed a significant decrease in the number and volume of new MRI lesions and a favourable safety profile. This article reviews data thus far present on the putative mechanisms of action of statins in the immunopathogenesis of MS. Furthermore, the role of statins as potential pharmacotherapy for MS is discussed in the context of the mechanisms of approved immunotherapies in MS, namely IFN-β and glatiramer acetate (GA).

AB - Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase and are widely prescribed as cholesterol-lowering agents. They are promising candidates for future treatment in multiple sclerosis (MS) as they have been shown to exhibit immunomodulatory effects. Recent reports have demonstrated that statins are effective in preventing and reversing chronic and relapsing experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Furthermore, in vitro experiments with human immune cells have documented an immunomodulatory mode of action of statins comparable to that of interferon (IFN)-β. An open label clinical trial assessing simvastatin in MS revealed a significant decrease in the number and volume of new MRI lesions and a favourable safety profile. This article reviews data thus far present on the putative mechanisms of action of statins in the immunopathogenesis of MS. Furthermore, the role of statins as potential pharmacotherapy for MS is discussed in the context of the mechanisms of approved immunotherapies in MS, namely IFN-β and glatiramer acetate (GA).

KW - Glatiramer acetate

KW - Immunomodulation

KW - Immunotherapy

KW - Interferon-β

KW - Multiple sclerosis

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=20444400236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444400236&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2005.03.030

DO - 10.1016/j.jns.2005.03.030

M3 - Article

C2 - 15949504

AN - SCOPUS:20444400236

VL - 233

SP - 173

EP - 177

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -